NOVARTIS N (NOVN)

Sell: 123.10 CHF|Buy: 123.12 CHF|Change: 2.10 (1.74%)

Open

121.04 CHF

Previous close

121.00 CHF

Trade high

123.20 CHF

Volume

4,177,152

Year high

123.20 CHF

Year low

81.10 CHF

Dividend yield

2.89%

Market capitalisation

234.89 bn CHF

P/E ratio

21.81

ISIN

CH0012005267

This share can be held in a Dealing account SIPP

Share price

Performance 10/02/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
NOVARTIS N	+ 0.67
More...

Company profile

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includesoff-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.